• Subscribe
  • Log In
  • Sign up for email updates
  • Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

The Texas Lawbook

Free Speech, Due Process and Trial by Jury

  • Appellate
  • Bankruptcy
  • Commercial Litigation
  • Corp. Deal Tracker/M&A
  • GCs/Corp. Legal Depts.
  • Firm Management
  • White-Collar/Regulatory

FDA Releases Final Guidance for Connected Medical Devices

© 2017 The Texas Lawbook.

spnsredx1l

By Timothy E. Hudson, Janelle L. Davis and Susan B. Murphy of Thompson & Knight

Tim Hudson
(Dec. 7) – With the overwhelming growth of medical devices connected to the “internet of things,” the Food and Drug Administration has scrutinized the accompanying cybersecurity risks and design issues closely and has issued a variety of guidance documents in recent years.

For example, the FDA in 2014 focused its guidance on cybersecurity threats during the research and development phase of a medical device’s life cycle. And in 2016, the agency expanded its focus and provided draft guidance concerning how medical device makers should monitor, identify and address cybersecurity vulnerabilities after introducing devices into the marketplace.

On Sept. 6, 2017, the FDA released its final guidance on Design Considerations and Premarket Submission Recommendations for Interoperable Medical Devices. Although the guidance is not binding, it provides medical device manufacturers with direction and recommendations with respect to design considerations when developing interoperable medical devices, as well as recommendations regarding information to include in premarket submissions and device labeling.

The FDA’s guidance highlights several issues that medical device manufacturers should consider in order to provide reasonable assurance that their connected devices are safe and effective. These issues include: (1) designing systems with interoperability as an objective (i.e., the ability to exchange and make use of information); (2) conducting appropriate verification, validation and risk management activities; and (3) specifying the relevant functional, performance and interface characteristics in a “user available” manner such as labeling. As set forth below, the FDA’s guidance discusses two main areas to help manufacturers provide appropriate safety and effectiveness: design implications and premarket submissions.

Design Implications

Janelle Davis

During the design process itself, the FDA recommends that manufacturers take into account the following issues associated with electronic interfaces that are incorporated into medical devices: (1) the purpose of the electronic interface and the types of data exchanges taking place; (2) the anticipated users and how the device will be used; (3) risk management related to the device, the network to which it is connected and other interfaced devices; (4) verification and validation of the device; (5) labeling considerations that are necessary to ensure predictable and safe connectivity; and (6) use of consensus standards related to interoperability.

The FDA’s guidance includes specific questions and concerns to consider in each of these six areas. For instance, there are more than a dozen different questions to consider when determining the purpose of a device’s electronic interface, including the need for time synchronization, the clinical context for the use of information exchanged in the interface, and the functional and performance requirements of the device as a result of the exchanged information. With regard to risk management considerations, the guidance advises manufacturers to consider, among other things, whether implementation and use of an electronic interface degrades the basic safety controls of the device. And when preparing device labeling, the FDA guidance suggests that manufacturers consider the best way to provide information regarding the intended use and accompanying risks of the device based on the device’s anticipated users and risk analysis.

Premarket Submissions

The FDA’s guidance also includes recommendations for manufacturers preparing premarket submissions. In short, the FDA recommends that manufacturers address each of the six issues mentioned above when preparing premarket submissions.

For example, the premarket submission should discuss any electronic interfaces found in the device, the purpose of each interface and the anticipated users of the interface. Manufacturers should also highlight whether the device is intended to exchange information with other devices, along with what information would be exchanged and how.

With respect to labeling considerations in a premarket submission, the FDA’s recommendations include providing information regarding the device’s electronic interface; instructions on how to use the device as it was intended; any limitations of the device’s connectivity; and precautions, warnings and contraindications.

In addition to these items, there may be a number of other things to include to ensure that the labeling complies with the requirements of 21 CFR parts 801 and 809, which address the regulatory requirements for medical device labeling. (For more on labeling, see FDA Guidance: Labeling—Regulatory Requirements for Medical Devices.)

The guidance does recognize that manufacturers “may need up to 60 days to perform activities to operationalize the policies within the guidance.” As such, if the FDA receives a premarket submission before or up to 60 days after the publication of its guidance, it does not intend to ask for the new information highlighted in the guidance document. It will, however, review the information if it is submitted.

Ultimately, the FDA’s primary concerns are that connected medical devices are able to safely exchange and use information and that patients and medical device operators are able to safely use interoperable medical devices. Although the information contained in the guidance is not an exhaustive summary of the issues that should be considered by manufacturers, it does provide a detailed starting point in this rapidly growing and changing area.

© 2017 The Texas Lawbook. Content of The Texas Lawbook is controlled and protected by specific licensing agreements with our subscribers and under federal copyright laws. Any distribution of this content without the consent of The Texas Lawbook is prohibited.

If you see any inaccuracy in any article in The Texas Lawbook, please contact us. Our goal is content that is 100% true and accurate. Thank you.

Primary Sidebar

Features

  • ‘Crucify Him! Crucify Him!’ The Story of the Mob and the Minister - Dr. Howard Jones stepped to the pulpit of his church 115 years ago six days after a riotous mob had terrorized his city. A judge, prosecutor and sheriff who facilitated the murderous herd were among his congregation. In one of the greatest sermons ever preached, he denounced lawlessness and cowardice. The result: Dr. Jones was fired as pastor. The mob burned down his home. He and his family fled for their lives. But his sermon is as true today and it was in 1906: "Whatsoever a man - or a community soweth - that shall they also reap." January 24, 2021Mark Curriden
  • M&A 2020 Rankings: Mergermarket Names the Top 50 Law Firms - For six of the past seven years, three law firms consistently rank as doing the most M&A deals in Texas. That did not change in 2020 - though all three saw a decline in deal activity. Only eight of the top 50 law firms involved in Texas dealmaking are Texas-based. Overall, M&A work declined for 27 of the top 50 firms and increased for only 19. The Texas Lawbook has the details. January 19, 2021Mark Curriden

GCs, Lawyers & Firms

  • FBFK Adds Stefani Carter to its Shareholder Ranks - Ferguson Braswell Fraser Kubasta has hired former Texas legislator Stefani Carter, who serves on the boards of two publicly traded REITs, as a shareholder in the firm’s commercial litigation practice.
  • Thompson Coburn Gains Healthcare Litigator in Dallas
  • State Tax Expert Jumps to Reed Smith
  • Austin Trial Lawyer Joins Butler Snow from Scott Douglass & McConnico
  • Bell Nunnally, Cole Schotz Gain IP Partners
  • Houston Deal Partner Leaves Latham for Willkie
  • Former Noble Energy Environmental Transactions Expert Joins White & Case
  • EY Tax Leader Moves to Mayer Brown
  • Locke Lord Lands Houston Litigator from Roberts Markel
More GCs, Lawyers & Firms

Firms in the News

Hover right to show full list

Akin Gump
Alston & Bird
Antero
Arclight
Baker Botts
Bakkt
Benchmark 
Bracewell
CAI Software
Charles Schwab
Cottonwood 
CRIS
Daikan
Desktop Metal
DIRTT
Element Markets
Eversheds Sutherland
EVgo
FBFK
Foley
Gibson Dunn
Golar LNG
Haynes and Boone
Hunton AK
Hygo Energy
InterContinental Exchange
Jackson Walker
Jones Day
Kirkland
Latham
Locke Lord
Marathon Oil
Mayer Brown
McDermott
New Fortress
Norton Rose Fulbright
ORIX Capital Partners
Petco
Pioneer Natural Resources
Porter Hedges
Proterra
Radley
Rise Fund
Shearman & Sterling
Sheppard Mullin
Simpson Thacher
Skadden
Specialty Welding
Switchback II
Thompson Coburn
Thompson Coe
Thompson & Knight
TPG
US Attorney's Office EDTX
V&E
Victory Park Capital
White & Case
Winstead

Lawyers in the News

Hover right to see full list

Doug Bacon
Jimmy Blacklock
Jane Bland
Denis Braham
Thomas Brandt
Heather L. Brown
Brett Busby
Stefani Carter
George Christian
Kevin Chumney
Lauren Corbeil
Steve Cox
Wade Crosnoe
Kevin Crews
Amy Curtis
Tess Dennis
Nick Dhesi
Sarah Dunn
Richard Frye
John Furlow
Michael Gibson
John Goodgame
Lisa Hearn
Robert Hughes
John Jackson
Monte James
Bryan Jones
Robert Kimball
Paul Knowlton
Dilen Kumar
Ramey Layne
Jessica Lewis
Doug Lionberger
Brice Lipman
Matt Lyons
Ryan Maierson
John McGowan
Morgan McPheeters
Matt Nadworny
David Oelman
Eric Otness
Joe Perillo
Aiesha Redmond
Alex Rose
Jeff Schlegel
Gregg Schmitt
Shamoil Shipchandler
Gerson Smoger
Lande Spottswood
David Staas
David Stone
Ram Sunkara
Rosalyn Tippett
Natalie Vesti
Mackenzie Wallace 
Kimberly Warnica
Donald Wilcox
Nicole Williams
Nathan Wolcott
Abbey Zuech

Footer

Who We Are

  • About Us
  • Our Team
  • Contact Us
  • Submit a News Tip

Stay Connected

  • Sign up for email updates
  • Article Submission Guidelines

Our Partners

  • Houston Chronicle
  • Dallas Business Journal
The Texas Lawbook logo

P.O. Box 543455
Grand Prairie, TX 75054

214.232.6783

info@texaslawbook.net

© Copyright 2021 The Texas Lawbook
The content on this website is protected under federal Copyright laws. Any use without the consent of The Texas Lawbook is prohibited.

Welcome to the New Texas Lawbook

Welcome to the new Texas Lawbook

We’ve been hard at work improving the way you experience the best law news in Texas. Today we are happy to launch our new and improved website. For more on what that means for you, check out this post from founder Mark Curriden.